StockData

BioCryst Pharmaceuticals vs Neurocrine Biosciences

BCRX and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and NBIX compare

Neurocrine Biosciences is the larger company, worth 8.8 times as much as BioCryst Pharmaceuticals ($16.9B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 34.4% for Neurocrine Biosciences).

Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with −40.9% at BioCryst Pharmaceuticals.

Neurocrine Biosciences scores higher on the StockData Score (19 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXNBIX
Size and price
Market cap$1.9B$16.9B
Share price$7.50$165.92
Change, 1 year5.9%14.5%
Change, 5 years−39.9%90.8%
Beta (5Y)0.580.29
Employees4351,800
StockData Score
Total score919 (better)
Valuation score13 (better)
Growth score45 (better)
Performance score25 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–24.3×
P/S2.0× (better)5.0×
P/B–4.6×
EV/EBITDA–20.7×
P/FCF5.1× (better)19.4×
PEG–0.55
FCF yield19.5% (better)5.2%
Fair value–$176.61
Margin of safety–6.1%
Growth
Revenue growth (TTM)68.7% (better)34.4%
Revenue growth, 5Y average118% (better)22.3%
Net income growth (TTM)–103%
EPS growth (TTM)–102%
EPS growth, 5Y average–2.3%
Profitability
Gross margin97.8%98.0% (better)
Operating margin−33.3%23.6% (better)
Net margin−40.9%20.9% (better)
FCF margin39.7% (better)25.8%
Return on equity–22.1%
Return on invested capital–23.7%
Financial health
Debt / equity–0.00
Interest coverage−4.2×–
Current ratio2.32 (better)1.87
Altman Z-score−3.837.55 (better)
Piotroski F-score77
Dividends and buybacks
Buyback yield–−0.74%
Shareholder yield0.00% (better)−0.74%
Ownership
Held by institutions103%99.5%
Held by insiders1.9%1.2%
Insider net buying, 12 months−$4.1M (better)−$74.4M
Short interest, % of float11.0%5.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.